NCT00654030View on ClinicalTrials.gov

Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

1650-G Vaccine

.6ml injection administered intradermally in the thigh at week 0 and week 4

Trial Locations (4)

40202

University of Louisville Hospital, Louisville

40422

Commonwealth Cancer Center, Danville

40536

University of Kentucky, Lexington

42303

Owensboro Medical Health System, Owensboro

All Listed Sponsors
collaborator

Kentucky Lung Cancer Research Program

OTHER

lead

Edward Hirschowitz

OTHER

NCT00654030 - Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter